新型冠状病毒肺炎的临床研究进展  

Clinical research progress of COVID-19

作　　者：魏胜兵 王金萍 罗雪 王亮[2] 李庆昌[2] 邱雪杉[2] 王恩华[2] WEI Sheng-bing;WANG Jin-ping;LUO Xue;WANG Liang;LI Qing-chang;QIU Xue-shan;WANG En-hua(Shenyang King Med Center for Clinical Laboratory Co.Ltd.,Shenyang 110164;Department of Pathology,College of Basic Medical Science,China Medical University,Shenyang 110122,China)

机构地区：[1]沈阳金域医学检验所有限公司,辽宁沈阳110164 [2]中国医科大学基础医学院病理学教研室,辽宁沈阳110122

出　　处：《解剖科学进展》2023年第4期433-436,共4页Progress of Anatomical Sciences

基　　金：国家自然科学基金(818742414);辽宁省科技厅社发公关及产业化资助项目(2017225010)。

摘　　要：新型冠状病毒病19(COVID-19)引起了一场紧急健康事件,COVID-19患者中呈现明显或者严重临床表现的主要为老年人和患有基础疾病的免疫力低下人群。与其它冠状病毒相比,SARS-CoV-2传染性更强、传播范围更广、更多无症状感染者,在积极干预治疗的情况下致死率相对较低。ACE2受体表达水平与病毒感染相关,ARDS、CRS综合征和机体免疫防御机制崩溃可能是导致患者最终死亡的主要原因。Coronavirus disease 19(COVID-19)causes an emergency health event,COVID-19 patients show obvious or serious clinical manifestations mainly in the elderly and those with underlying diseases.Compared with other coronaviruses,SARS-CoV-2 is more infectious,wider transmission range,more asymptomatic infections and lower mortality rate under active intervention and treatment.The expression of ACE2 receptor is associated with viral infection.ARDS,CRS syndrome and collapse of immune defense may be the main causes of death.

关 键 词：机体免疫防御 免疫力低下 无症状感染 临床研究进展 ACE2 新型冠状病毒 病毒感染 传播范围 

分 类 号：R563.1[医药卫生—呼吸系统]